|
|
 |
|
Viewing report
|
|
|
|
Amgen Inc.: PharmaVitae Report
Datamonitor, June 2011, Pages: 93
Introduction
This analysis examines the historical and forecast performance for Amgen in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs
Features and benefits
- Gain insight into Amgen's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Amgen over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Amgen's performance against key rivals in the prescription pharmaceutical sector
- Assess the importance of the recently approved Prolia/Xgeva (denosumab) in shaping Amgen's future sales performance
|
|
|
|
